## 03/22/2005 16:14 FAX 312 913 0002

## AKIMA-DTSV 23 MAR 2005

PATENT

	UNITED STATES PATENT AI	ND	TRADEMARK OF	FICE
	(Cașe No. MBHB02,	74	2-F (400/131))	
IN THI	E APPLICATION OF:	)	•	
		)		
McSwiggen, et al.			Examiner:	To Be Assigned
	•	)		
Serial	10/665,951	)	Group Art Unit:	1635.
No.		)		
Filed:	September 18, 2003	)	Confirmation No.:	8325
		)		·
Title	RNA Interference Mediated Inhibition	)	Fax No.:	(703) 746-9195
	Of Vascular Endothelial Growth Factor	)		
	And Vascular Endothelial Growth Factor	)		
	Receptor Gene Expression Using Short	)	,	
	Interfering Nucleic Acid (siNA)	)		
	TRANSMITTA	L	<u>LETTER</u>	
Mail St	op OPE			
	ssioner for Patents			
P.O. Bo	x 1450			
Alexano	dria, Virginia 22313-1450			•
Attn:	Office of Initial Patent Examination's			

#### Dear Sir:

In regard to the above identified application,

We are transmitting herewith the attached: 1.

Filing Receipt Corrections

- a) Request for Corrected Filing Receipt
- b) Copy of Filing Receipt with changes noted thereon
- 2. With respect to fees:
  - a) It is believed no fee is due at this time.
- 3. GENERAL AUTHORIZATION: Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.
- CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifics that this 4, Transmittal Letter and the paper, as described in paragraph 1, are being transmitted via facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 (Fax No. (703) 746-9195) on March 22, 2005.

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff LLP

March 22, 2005

Registration No. 47,132

-	4 76	ויקווי	
$-\nu$	A .	. K. I	NT
1 4	~ ~	1.77	

### UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. MBHB02,742-F (400/131))

IN THE APPLICATION OF: McSwiggen, et al. Examiner: To Be Assigned Serial No. 10/665,951 Group Art Unit: 1635 Filed: September 18, 2003 Confirmation No.: 8325 RNA Interference Mediated Inhibition Of Title Vascular Endothelial Growth Factor And Vascular Endothelial Growth Factor Receptor Gene Expression Using Short ) Interfering Nucleic Acid (siNA)

#### REQUEST FOR CORRECTED FILING RECEIPT

Mail Stop OIPE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Attention: Office of Initial Patent Examination's

Filing Receipts Corrections

- Attached is a copy of a corrected filing receipt received from the PTO in the abovereferenced application for which issuance of a new corrected filing receipt is respectfully requested.
- 2. There is an error with respect to the following data, which is incorrectly entered.

#### Error in

Domestic Priority data as claimed by applicant
This application is a CIP of 10/664,767 09/16/2003 ABN
which is a CIP of PCT/US03/05022 02/20/2003
which claims benefit of 60/358,580 02/20/2002
and claims benefit of 60/363,124 03/11/2002
and claims benefit of 60/386,782 06/06/2002

APPLICATION NO. 10/665,951 ATTORNEY DOCKET NO. MBI1B02-742-F (400/131)

and claims benefit of 60/393, 796 07/03/2002 and claims benefit of 60/399,348 07/29/2002 and claims benefit of 60/406,784 08/29/2002 and claims benefit of 60/408,378 09/05/2002 and claims benefit of 60/409,293 09/09/2002 and claims benefit of 60/409,293 09/09/2002 and claims benefit of 60/440,129 01/15/2003 and is a CIP of 10/306,747 11/27/2002 which claims benefit of 60/334,461 11/30/2001 and said PCT/US03/05022 02/20/2003 is a CIP of 10/287,949 11/04/2002

#### **Correct Data**

Domestic Priority data as claimed by applicant: This application is a CIP of 10/664,767 09/16/2003 which is a CIP of PCT/US03/05022 02/20/2003 which claims benefit of 60/358,580 02/20/2002 and claims benefit of 60/363,124 03/11/2002 and claims benefit of 60/386,782 06/06/2002 and claims benefit of 60/393, 796 07/03/2002 and claims benefit of 60/399,348 07/29/2002 and claims benefit of 60/406,784 08/29/2002 and claims benefit of 60/408,378 09/05/2002 and claims benefit of 60/409,293 09/09/2002 and claims benefit of 60/440,129 01/15/2003 and said PCT/US03/05022 02/20/2003 is a CIP of 10/306,747 \1/27/2002 which claims benefit of 60/334,461 11/30/2001 and said PCT/US03/05022 02/20/2003 is a CIP of 10/287,949 11/04/2002

14-Degree Berner Helbert & Bischoff LLP 300 South Warren Drive, Suite 3100 Copywyr, Helberts 60604 Treps from 1312) 913-0004 APPLICATION NO. 10/665,951 ATTORNEY DOCKET NO. MBHB02-742-F (400/131)

#### and a CIP of PCT/US02/17674 05/29/02

Applicant believes that no fee is due in connection with this filing, however, if a fee
is due, the Commissioner is authorized to charge our deposit account number 131249.

Respectfully submitted, McDonnell, Boehnen, Hulbert & Berghoff LLP

Date: March 22, 2005

Anita J. Terpstra, Ph.D. Registration No. 47,132



#### United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Parent and Trademark Offices Address COMMERCIONER FOR PATENTS P.O. DOZ 1450 Alexandra, Vignia 2010-1450 www.unipulaw

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/665,951	09/18/2003	1635	626	MBHB02-742-F (400.131)	19	36	4

020306 MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP 300 S. WACKER DRIVE 32ND FLOOR CHICAGO, IL 60606 CONFIRMATION NO. 8325 CORRECTED FILING RECEIPT OC000000015419979\*

Date Mailed: 03/10/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filling Receipt, please write to the Office of Initial Patent Examination's Filling Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filling Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filling Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filling Receipt incorporating the requested corrections (if appropriate).

#### Applicant(s)

James McSwiggen, Boulder, CO; Leonid Beigelman, Longmont, CO; Pamela Pavco, Lafayette, CO;

#### Assignment For Published Patent Application

Sima Therapeutics, Inc., Boulder, CO

DOCKETED

MAR 15 2005

DUE DATE OF THE BY:

Power of Attorney: The patent practitioners associated with Customer Number 020306.

#### Domestic Priority data as claimed by applicant

This application is a CIP of 10/664,767 09/16/2003 ABN, which is a CIP of PCT/US03/05022 02/20/2003 which claims benefit of 60/358,580 02/20/2002 and claims benefit of 60/363,124 03/11/2002 and claims benefit of 60/386,782 06/06/2002 and claims benefit of 60/393,796 07/03/2002 and claims benefit of 60/399,348 07/29/2002 and claims benefit of 60/406,784 08/29/2002 and claims benefit of 60/408,378 09/05/2002 and claims benefit of 60/409,293 09/09/2002 and claims benefit of 60/409,293 09/09/2002 and claims benefit of 60/440,129 01/15/2003 and is a CIP of 10/306,747 11/27/2002 which claims benefit of 60/334,461 11/30/2001 and said PCT/US03/05022 02/20/2003 is a CIP of 10/287,949 11/04/2002

This application is a CIP of 10/664,767 09/16/2003 which is a CIP of PCT/US03/05022 02/20/2003 which claims benefit of 60/358,580 02/20/2002 and claims benefit of 60/363,124 03/11/2002 and claims benefit of 60/386,782 06/06/2002 and claims benefit of 60/393, 796 07/03/2002 and claims benefit of 60/399,348 07/29/2002 and claims benefit of 60/406,784 08/29/2002 and claims benefit of 60/408,378 09/05/2002 and claims benefit of 60/409,293 09/09/2002 and claims benefit of 60/440,129 01/15/2003 and said PCT/US03/05022 02/20/2003 is a CIP of 10/306,747 11/27/2002 which claims benefit of 60/334,461 11/30/2001 and said PCT/US03/05022 02/20/2003 is a CIP of 10/287,949 11/04/2002 and a CIP of PCT/US02/17674 05/29/02

#### Foreign Applications

If Required, Foreign Filing License Granted: 12/12/2003

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is US10/665.951

Projected Publication Date: Not Applicable

Non-Publication Request: No

Early Publication Request: No

\*\* SMALL ENTITY \*\*

Title

RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)

**Preliminary Class** 

514

# LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

#### GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING

LICENSE GRANTED\* DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).